Psoriasis drug may help hearts, study finds
NCT ID NCT04271540
First seen Jan 05, 2026 · Last updated May 07, 2026 · Updated 23 times
Summary
This study tested whether tildrakizumab, an FDA-approved psoriasis medication, can improve blood flow to the heart in people with moderate-to-severe psoriasis. 36 adults with psoriasis and heart disease risk took the drug for 6 months. Researchers used heart scans to measure changes in coronary flow reserve, a key indicator of heart health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.